• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

    7/8/22 10:02:55 AM ET
    $A
    $AAL
    $AMH
    $APRE
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Air Freight/Delivery Services
    Consumer Discretionary
    Get the next $A alert in real time by email

     

    Upgrades

    • According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from Neutral to Outperform. Diebold Nixdorf earned $1.61 in the first quarter, compared to $0.29 in the year-ago quarter. At the moment, the stock has a 52-week-high of $12.55 and a 52-week-low of $2.12. Diebold Nixdorf closed at $2.49 at the end of the last trading period.
    • According to Guggenheim, the prior rating for Eversource Energy (NYSE:ES) was changed from Neutral to Buy. Eversource Energy earned $1.30 in the first quarter, compared to $1.06 in the year-ago quarter. The current stock performance of Eversource Energy shows a 52-week-high of $94.63 and a 52-week-low of $77.06. Moreover, at the end of the last trading period, the closing price was at $83.59.
    • Cowen & Co. upgraded the previous rating for Lennox International Inc (NYSE:LII) from Market Perform to Outperform. In the first quarter, Lennox International showed an EPS of $2.36, compared to $2.27 from the year-ago quarter. The stock has a 52-week-high of $354.62 and a 52-week-low of $182.85. At the end of the last trading period, Lennox International closed at $218.15.
    • According to Cowen & Co., the prior rating for Trane Technologies PLC (NYSE:TT) was changed from Market Perform to Outperform. Trane Technologies earned $1.12 in the first quarter, compared to $1.01 in the year-ago quarter. The current stock performance of Trane Technologies shows a 52-week-high of $207.06 and a 52-week-low of $120.64. Moreover, at the end of the last trading period, the closing price was at $130.77.
    • According to Morgan Stanley, the prior rating for XPO Logistics Inc (NYSE:XPO) was changed from Equal-Weight to Overweight. For the first quarter, XPO Logistics had an EPS of $1.25, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $144.96 and a 52-week-low of $45.25. XPO Logistics closed at $48.46 at the end of the last trading period.
    • B of A Securities upgraded the previous rating for The Vita Coco Co Inc (NASDAQ:COCO) from Neutral to Buy. In the first quarter, Vita Coco showed an EPS of $0.04, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $18.61 and a 52-week-low of $7.51. At the end of the last trading period, Vita Coco closed at $9.90.
    • For The Interpublic Group of Companies Inc (NYSE:IPG), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the first quarter, Interpublic Gr of Cos showed an EPS of $0.47, compared to $0.45 from the year-ago quarter. The current stock performance of Interpublic Gr of Cos shows a 52-week-high of $39.98 and a 52-week-low of $26.36. Moreover, at the end of the last trading period, the closing price was at $27.89.
    • According to Wells Fargo, the prior rating for Omnicom Group Inc (NYSE:OMC) was changed from Equal-Weight to Overweight. In the first quarter, Omnicom Group showed an EPS of $1.39, compared to $1.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $91.61 and a 52-week-low of $61.31. Omnicom Group closed at $63.84 at the end of the last trading period.

    See all analyst ratings upgrades.

     

    Downgrades

    • According to Morgan Stanley, the prior rating for Zenvia Inc (NASDAQ:ZENV) was changed from Overweight to Equal-Weight. The stock has a 52-week-high of $20.02 and a 52-week-low of $1.84. At the end of the last trading period, Zenvia closed at $2.30.
    • According to Argus Research, the prior rating for American Airlines Group Inc (NASDAQ:AAL) was changed from Buy to Hold. For the first quarter, American Airlines Group had an EPS of $2.32, compared to year-ago quarter EPS of $4.32. The stock has a 52-week-high of $22.35 and a 52-week-low of $11.93. At the end of the last trading period, American Airlines Group closed at $14.10.
    • Wells Fargo downgraded the previous rating for Audacy Inc (NYSE:AUD) from Equal-Weight to Underweight. In the first quarter, Audacy showed an EPS of $0.10, compared to $0.07 from the year-ago quarter. The current stock performance of Audacy shows a 52-week-high of $4.19 and a 52-week-low of $0.91. Moreover, at the end of the last trading period, the closing price was at $0.98.
    • Redburn Partners downgraded the previous rating for PayPal Holdings Inc (NASDAQ:PYPL) from Buy to Neutral. For the first quarter, PayPal Holdings had an EPS of $0.88, compared to year-ago quarter EPS of $1.22. The current stock performance of PayPal Holdings shows a 52-week-high of $310.16 and a 52-week-low of $67.58. Moreover, at the end of the last trading period, the closing price was at $75.04.
    • For Six Flags Entertainment Corp (NYSE:SIX), Citigroup downgraded the previous rating of Buy to Neutral. In the first quarter, Six Flags Entertainment showed an EPS of $0.76, compared to $1.12 from the year-ago quarter. The current stock performance of Six Flags Entertainment shows a 52-week-high of $47.24 and a 52-week-low of $19.91. Moreover, at the end of the last trading period, the closing price was at $23.46.
    • For Agilent Technologies Inc (NYSE:A), Citigroup downgraded the previous rating of Buy to Neutral. For the second quarter, Agilent Technologies had an EPS of $1.13, compared to year-ago quarter EPS of $0.97. The stock has a 52-week-high of $179.57 and a 52-week-low of $112.52. At the end of the last trading period, Agilent Technologies closed at $123.15.
    • Wells Fargo downgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE:CCO) from Overweight to Equal-Weight. For the first quarter, Clear Channel Outdoor had an EPS of $0.19, compared to year-ago quarter EPS of $0.60. At the moment, the stock has a 52-week-high of $4.10 and a 52-week-low of $1.01. Clear Channel Outdoor closed at $1.27 at the end of the last trading period.
    • For Illinois Tool Works Inc (NYSE:ITW), UBS downgraded the previous rating of Buy to Neutral. For the first quarter, Illinois Tool Works had an EPS of $2.11, compared to year-ago quarter EPS of $2.11. The stock has a 52-week-high of $249.81 and a 52-week-low of $177.03. At the end of the last trading period, Illinois Tool Works closed at $185.64.
    • According to UBS, the prior rating for Kennametal Inc (NYSE:KMT) was changed from Neutral to Sell. In the third quarter, Kennametal showed an EPS of $0.47, compared to $0.32 from the year-ago quarter. At the moment, the stock has a 52-week-high of $41.22 and a 52-week-low of $21.62. Kennametal closed at $24.31 at the end of the last trading period.
    • For Upstart Holdings Inc (NASDAQ:UPST), JMP Securities downgraded the previous rating of Market Outperform to Market Perform. In the first quarter, Upstart Hldgs showed an EPS of $0.61, compared to $0.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of $401.49 and a 52-week-low of $25.43. Upstart Hldgs closed at $33.74 at the end of the last trading period.
    • For iHeartMedia Inc (NASDAQ:IHRT), Wells Fargo downgraded the previous rating of Overweight to Equal-Weight. In the first quarter, iHeartMedia showed an EPS of $0.33, compared to $1.73 from the year-ago quarter. The stock has a 52-week-high of $27.62 and a 52-week-low of $7.03. At the end of the last trading period, iHeartMedia closed at $7.36.
    • According to HC Wainwright & Co., the prior rating for Meridian Bioscience Inc (NASDAQ:VIVO) was changed from Buy to Neutral. For the second quarter, Meridian Bioscience had an EPS of $0.66, compared to year-ago quarter EPS of $0.56. The current stock performance of Meridian Bioscience shows a 52-week-high of $34.38 and a 52-week-low of $17.04. Moreover, at the end of the last trading period, the closing price was at $33.27.
    • According to Piper Sandler, the prior rating for Huntington Bancshares Inc (NASDAQ:HBAN) was changed from Overweight to Neutral. In the first quarter, Huntington Bancshares showed an EPS of $0.32, compared to $0.48 from the year-ago quarter. The current stock performance of Huntington Bancshares shows a 52-week-high of $17.79 and a 52-week-low of $11.67. Moreover, at the end of the last trading period, the closing price was at $12.38.

    See all analyst ratings downgrades.

     

    Initiations

    • With an Overweight rating, Capital One initiated coverage on American Homes 4 Rent (NYSE:AMH). The price target seems to have been set at $43.00 for American Homes 4 Rent. American Homes 4 Rent earned $0.38 in the first quarter, compared to $0.32 in the year-ago quarter. The stock has a 52-week-high of $44.07 and a 52-week-low of $32.60. At the end of the last trading period, American Homes 4 Rent closed at $35.97.
    • With an Outperform rating, Northland Capital Markets initiated coverage on Bloom Energy Corp (NYSE:BE). The price target seems to have been set at $28.00 for Bloom Energy. In the first quarter, Bloom Energy showed an EPS of $0.32, compared to $0.07 from the year-ago quarter. The current stock performance of Bloom Energy shows a 52-week-high of $37.01 and a 52-week-low of $11.47. Moreover, at the end of the last trading period, the closing price was at $18.37.
    • Jefferies initiated coverage on CCC Intelligent Solutions Holdings Inc (NYSE:CCCS) with a Buy rating. The price target for CCC Intelligent Solutions is set to $12.00. CCC Intelligent Solutions earned $0.08 in the first quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $13.46 and a 52-week-low of $7.41. At the end of the last trading period, CCC Intelligent Solutions closed at $9.58.
    • With an Outperform rating, Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ:RCKT). The price target seems to have been set at $22.00 for Rocket Pharmaceuticals. In the first quarter, Rocket Pharmaceuticals showed an EPS of $0.67, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $49.66 and a 52-week-low of $7.57. Rocket Pharmaceuticals closed at $16.15 at the end of the last trading period.
    • Benchmark initiated coverage on DPCM Capital Inc (NYSE:XPOA) with a Buy rating. The price target for DPCM Capital is set to $14.00. At the moment, the stock has a 52-week-high of $10.33 and a 52-week-low of $9.65. DPCM Capital closed at $9.91 at the end of the last trading period.
    • With a Buy rating, Chardan Capital initiated coverage on Immuneering Corp (NASDAQ:IMRX). The price target seems to have been set at $18.00 for Immuneering. Immuneering earned $0.49 in the first quarter, compared to $1.26 in the year-ago quarter. The stock has a 52-week-high of $33.99 and a 52-week-low of $3.74. At the end of the last trading period, Immuneering closed at $5.65.
    • Benchmark initiated coverage on NOW Inc (NYSE:DNOW) with a Buy rating. The price target for NOW is set to $13.00. For the first quarter, NOW had an EPS of $0.14, compared to year-ago quarter EPS of $0.04. At the moment, the stock has a 52-week-high of $12.55 and a 52-week-low of $6.83. NOW closed at $9.71 at the end of the last trading period.
    • With a Buy rating, Benchmark initiated coverage on MRC Global Inc (NYSE:MRC). The price target seems to have been set at $14.00 for MRC Global. MRC Global earned $0.17 in the first quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.45 and a 52-week-low of $6.38. MRC Global closed at $9.36 at the end of the last trading period.
    • With an Outperform rating, Oppenheimer initiated coverage on Blueprint Medicines Corp (NASDAQ:BPMC). The price target seems to have been set at $80.00 for Blueprint Medicines. For the first quarter, Blueprint Medicines had an EPS of $1.79, compared to year-ago quarter EPS of $1.72. The stock has a 52-week-high of $117.86 and a 52-week-low of $43.46. At the end of the last trading period, Blueprint Medicines closed at $54.81.
    • With an Outperform rating, Oppenheimer initiated coverage on Vertex Energy Inc (NASDAQ:VTNR). The price target seems to have been set at $18.00 for Vertex Energy. For the first quarter, Vertex Energy had an EPS of $0.12, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $18.10 and a 52-week-low of $3.30. At the end of the last trading period, Vertex Energy closed at $11.13.
    • Wedbush initiated coverage on Aprea Therapeutics Inc (NASDAQ:APRE) with an Outperform rating. The price target for Aprea Therapeutics is set to $3.00. In the first quarter, Aprea Therapeutics showed an EPS of $0.36, compared to $0.46 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.89 and a 52-week-low of $0.62. Aprea Therapeutics closed at $0.80 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $AAL
    $AMH
    $APRE

    CompanyDatePrice TargetRatingAnalyst
    XPO Inc.
    $XPO
    2/11/2026$210.00Positive → Neutral
    Susquehanna
    PayPal Holdings Inc.
    $PYPL
    2/10/2026$58.00 → $39.00Sell
    Truist
    Bloom Energy Corporation
    $BE
    2/6/2026$105.00 → $160.00Hold
    TD Cowen
    PayPal Holdings Inc.
    $PYPL
    2/4/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    PayPal Holdings Inc.
    $PYPL
    2/4/2026$47.00Buy → Hold
    HSBC Securities
    PayPal Holdings Inc.
    $PYPL
    2/4/2026$42.00Buy → Hold
    Canaccord Genuity
    PayPal Holdings Inc.
    $PYPL
    2/4/2026$51.00Sell → Neutral
    Compass Point
    Huntington Bancshares Incorporated
    $HBAN
    2/3/2026$21.00Outperform
    Evercore ISI
    More analyst ratings

    $A
    $AAL
    $AMH
    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Beam S Craig bought $4,969 worth of shares (157 units at $31.65), increasing direct ownership by 0.59% to 26,665 units (SEC Form 4)

    4 - PEOPLES BANCORP INC (0000318300) (Issuer)

    1/23/26 2:11:54 PM ET
    $PEBO
    Major Banks
    Finance

    $A
    $AAL
    $AMH
    $APRE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 15, 2023 - FDA Roundup: December 15, 2023

    For Immediate Release: December 15, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the breast implants web pages to share the latest information on: Risks and complications related to breast implants  Reports of squamous cell carcinoma (SCC), various lymphomas other than Breast Implants Associated Anaplastic Large

    12/15/23 3:14:20 PM ET
    $DNOW
    Oil and Gas Field Machinery
    Consumer Discretionary

    October 24, 2023 - FDA Roundup: October 24, 2023

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Friday, the FDA approved Medtronic’s Aurora EV-ICD System for the treatment of patients who have experienced, or are at significant risk of developing, life-threatening abnormally fast heart rhythms (ventricular tachyarrhythmias). The system is composed of

    10/24/23 2:26:32 PM ET
    $DNOW
    Oil and Gas Field Machinery
    Consumer Discretionary

    $A
    $AAL
    $AMH
    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    XPO, Inc. downgraded by Susquehanna with a new price target

    Susquehanna downgraded XPO, Inc. from Positive to Neutral and set a new price target of $210.00

    2/11/26 7:51:34 AM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    Truist reiterated coverage on PayPal with a new price target

    Truist reiterated coverage of PayPal with a rating of Sell and set a new price target of $39.00 from $58.00 previously

    2/10/26 7:52:35 AM ET
    $PYPL
    Diversified Commercial Services
    Industrials

    TD Cowen reiterated coverage on Bloom Energy with a new price target

    TD Cowen reiterated coverage of Bloom Energy with a rating of Hold and set a new price target of $160.00 from $105.00 previously

    2/6/26 8:24:09 AM ET
    $BE
    Industrial Machinery/Components
    Energy

    $A
    $AAL
    $AMH
    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sabre, PayPal, and Mindtrip partner to deliver the industry's first end-to-end agentic AI experience for travel

    An unprecedented collaboration combines AI, trusted identity, payments, and enterprise travel infrastructure to create personalized experiences and usher the travel ecosystem into the next era. SOUTHLAKE, Texas and SAN JOSE, Calif. and PALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ --  Sabre Corporation (NASDAQ:SABR),  PayPal Holdings (NASDAQ:PYPL), and Mindtrip, today announced a strategic partnership to deliver a next-generation agentic AI experience that reimagines how consumers discover, plan, book, and manage travel. The collaboration unites Mindtrip's agentic consumer platform, PayPal's agentic commerce capabilities, and Sabre's unparalleled enterprise-grade travel technology and agenti

    2/12/26 9:00:00 AM ET
    $PYPL
    $SABR
    Diversified Commercial Services
    Industrials
    Computer Software: Programming Data Processing
    Technology

    Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

    New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilitie

    2/12/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iHeartMedia, Inc. to Report Quarterly and Annual Financial Results on March 2, 2026

    iHeartMedia, Inc. (NASDAQ:IHRT) announced today that on Monday March 2nd, 2026, it will issue financial results for the quarter and year ending December 31, 2025. The company will conduct a conference call at 4:30 p.m. (ET), following the release of its earnings announcement, to discuss its financial results and business outlook. A live audio webcast of the call will be available on the Investors homepage of iHeartMedia's website (https://investors.iheartmedia.com/) beginning at 4:30 p.m. (ET) on March 2nd. The conference call can also be accessed by dialing (888) 596-4144 (domestic) or +1 646 968-2525 (international) using PIN number 8885116 followed by # key. Please call at least five m

    2/12/26 8:30:00 AM ET
    $IHRT
    Broadcasting
    Consumer Discretionary

    $A
    $AAL
    $AMH
    $APRE
    SEC Filings

    View All

    Diebold Nixdorf Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DIEBOLD NIXDORF, Inc (0000028823) (Filer)

    2/12/26 7:05:17 AM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    Amendment: SEC Form SCHEDULE 13D/A filed by Clear Channel Outdoor Holdings Inc.

    SCHEDULE 13D/A - Clear Channel Outdoor Holdings, Inc. (0001334978) (Subject)

    2/11/26 6:30:48 PM ET
    $CCO
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Clear Channel Outdoor Holdings Inc.

    SCHEDULE 13D/A - Clear Channel Outdoor Holdings, Inc. (0001334978) (Subject)

    2/11/26 4:30:39 PM ET
    $CCO
    Advertising
    Consumer Discretionary

    $A
    $AAL
    $AMH
    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President & CFO Kuehn Christopher J sold $1,105,394 worth of Ordinary Shares (2,389 units at $462.70), decreasing direct ownership by 4% to 60,486 units (SEC Form 4)

    4 - Trane Technologies plc (0001466258) (Issuer)

    2/11/26 4:07:01 PM ET
    $TT
    Auto Parts:O.E.M.
    Industrials

    Chair and CEO Regnery David S sold $2,585,018 worth of Ordinary Shares (5,588 units at $462.60), decreasing direct ownership by 5% to 96,948 units (SEC Form 4)

    4 - Trane Technologies plc (0001466258) (Issuer)

    2/11/26 4:06:17 PM ET
    $TT
    Auto Parts:O.E.M.
    Industrials

    Group President, Americas Simmons Donald E. sold $380,230 worth of Ordinary Shares (822 units at $462.57), decreasing direct ownership by 18% to 3,819 units (SEC Form 4)

    4 - Trane Technologies plc (0001466258) (Issuer)

    2/11/26 4:05:54 PM ET
    $TT
    Auto Parts:O.E.M.
    Industrials

    $A
    $AAL
    $AMH
    $APRE
    Leadership Updates

    Live Leadership Updates

    View All

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PayPal Appoints Enrique Lores as Chief Executive Officer and David W. Dorman as Independent Board Chair

    SAN JOSE, Calif., Feb. 3, 2026 /PRNewswire/ -- PayPal Holdings Inc. (NASDAQ:PYPL) today announced that its Board of Directors has appointed Enrique Lores as President and CEO, effective March 1, 2026. Lores, who has served on the PayPal Board for nearly five years and as Board Chair since July 2024, succeeds Alex Chriss. To ensure a seamless transition, Jamie Miller, Chief Financial and Operating Officer, will serve as Interim CEO until Lores assumes the role. David W. Dorman has been appointed as Independent Board Chair, effective immediately. Today's appointment follows a de

    2/3/26 6:58:00 AM ET
    $PYPL
    Diversified Commercial Services
    Industrials

    $A
    $AAL
    $AMH
    $APRE
    Financials

    Live finance-specific insights

    View All

    iHeartMedia, Inc. to Report Quarterly and Annual Financial Results on March 2, 2026

    iHeartMedia, Inc. (NASDAQ:IHRT) announced today that on Monday March 2nd, 2026, it will issue financial results for the quarter and year ending December 31, 2025. The company will conduct a conference call at 4:30 p.m. (ET), following the release of its earnings announcement, to discuss its financial results and business outlook. A live audio webcast of the call will be available on the Investors homepage of iHeartMedia's website (https://investors.iheartmedia.com/) beginning at 4:30 p.m. (ET) on March 2nd. The conference call can also be accessed by dialing (888) 596-4144 (domestic) or +1 646 968-2525 (international) using PIN number 8885116 followed by # key. Please call at least five m

    2/12/26 8:30:00 AM ET
    $IHRT
    Broadcasting
    Consumer Discretionary

    Diebold Nixdorf Reports 2025 Fourth Quarter and Full-Year Financial Results; Company Grew Revenue and Adjusted EBITDA, and More Than Doubled Free Cash Flow in FY 2025

    Company establishes new 2026 financial outlook, above previous targets provided at 2025 Investor DayOrder entry grew 17%, with revenue growth of ~2% YoY Free cash flow more than doubled YoY to a company recordAdjusted EPS more than doubled YoY Executing on new $200 million share repurchase program following completion of initial $100 million program in Q4; repurchased approximately $128 million of shares, or ~6% of the company's total shares outstanding in FY 2025Materials and investor call information available at http://www.dieboldnixdorf.com/earningsNORTH CANTON, Ohio, Feb. 12, 2026 /PRNewswire/ -- Diebold Nixdorf (NYSE:DBD), a world leader in transforming the way people bank and shop, to

    2/12/26 7:00:00 AM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AAL
    $AMH
    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Clear Channel Outdoor Holdings Inc.

    SC 13D/A - Clear Channel Outdoor Holdings, Inc. (0001334978) (Subject)

    12/4/24 5:00:38 PM ET
    $CCO
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care